Hematology

Blood Transfusion in India and UAE | Complete Patient Guide

Q: What is the cost of blood transfusion therapy in India vs. the UAE?

The cost of blood transfusion therapy in India at NABH/JCI-accredited hospitals typically ranges from USD 400 to USD 3,500, depending on the number of units transfused, the type of blood components required (e.g., standard leukoreduced packed red blood cells vs. irradiated, pathogen-reduced, or apheresis platelets), the complexity of the protocol (single transfusion episode vs. exchange transfusion via apheresis vs. multi-day Massive Transfusion Protocol support), and the duration of hospitalization. This cost includes blood bank processing fees, bedside nursing monitoring, IV consumables, pre- and post-transfusion laboratory investigations (CBC, crossmatch, coagulation studies), and standard medications. In the UAE (Dubai or Abu Dhabi), the same scope of care at JCI/DHA-accredited private hospitals ranges from USD 900 to USD 8,000 — approximately 50–65% higher than India — reflecting the premium pricing structure of Gulf healthcare, luxury hospital infrastructure, and higher operational costs. For patients requiring chronic transfusion programs (e.g., thalassemia major receiving transfusions every 3–4 weeks, or MDS patients), the annual cost differential between India and the UAE can be substantial, making India an especially compelling destination for long-term treatment planning. GAF Healthcare provides transparent, itemized cost estimates before travel so patients can plan accurately with no hidden charges.

Q: How long do I need to stay in the country before I am fit to fly home after blood transfusion therapy?

For the majority of patients undergoing a straightforward elective transfusion (1–3 units of packed red blood cells for symptomatic anemia), the total in-country stay required before being cleared for long-haul international flight is typically 5–10 days. The key fit-to-fly criteria assessed by the treating hematologist are: (1) post-transfusion hemoglobin ≥8 g/dL — this threshold is critical because commercial aircraft cabin pressure is equivalent to an altitude of approximately 6,000–8,000 feet, where ambient oxygen partial pressure is reduced, and patients with hemoglobin below this level risk in-flight hypoxemia; (2) absence of active bleeding, hemolytic reaction, or respiratory compromise; (3) stable vital signs for at least 48 hours post-transfusion; and (4) no ongoing requirement for further transfusion sessions. Patients who have undergone automated exchange transfusion for sickle cell disease are typically cleared to fly within 7–10 days once HbS% has been confirmed below 30% by HPLC and clinical stability is established. Patients receiving their first session of a chronic transfusion program (thalassemia, MDS) may be discharged in 3–5 days with a planned return for subsequent sessions. Patients with concurrent conditions such as heart failure, acute chest syndrome, or severe coagulopathy requiring extended management may need a 2–4 week stay. GAF Healthcare's medical team coordinates directly with the treating physician to provide each patient with an individualized fit-to-fly certificate and, where needed, arranges in-flight supplemental oxygen through the airline's medical desk.

Q: What is the success rate of blood transfusion therapy, and how is it defined?

At NABH/JCI-accredited hospitals in India and DHA/JCI-accredited hospitals in the UAE, blood transfusion therapy achieves a procedural success rate of 97–99% when success is defined as: (a) achievement of the target hemoglobin increment (approximately 1 g/dL per unit of packed red blood cells in a standard 70 kg adult); (b) correction of the presenting coagulopathy to within safe range (INR <1.5 after FFP, fibrinogen ≥1.5 g/L after cryoprecipitate, platelet count above the therapeutic threshold after platelet transfusion); or (c) resolution of the hemorrhagic or hypoxic clinical emergency without serious transfusion-related adverse events. Serious adverse events — including acute hemolytic transfusion reactions, TRALI, and anaphylaxis — occur in fewer than 0.1–0.5% of transfusion episodes at accredited centers using NAT-screened blood products, pre-storage leukoreduction, and mandatory electronic bedside verification. It is important to understand that transfusion is a therapeutic intervention, not a cure for the underlying cause of anemia or coagulopathy; the success of the overall treatment plan depends on concurrent management of the root cause (e.g., iron supplementation for iron-deficiency anemia, chemotherapy for bone marrow infiltration, surgical hemostasis for traumatic hemorrhage). GAF Healthcare-affiliated hematologists provide a comprehensive treatment plan addressing both the immediate transfusion need and the long-term management strategy, including monitoring for iron overload in patients on chronic transfusion programs and initiation of chelation therapy (deferasirox, deferoxamine) when serum ferritin exceeds 1,000 ng/mL.

Blood transfusion therapy involves the intravenous administration of whole blood or specific blood components — including packed red blood cells (pRBCs), fresh frozen plasma (FFP), platelets, and cryoprecipitate — to restore oxygen-carrying capacity, correct coagulopathies, or treat hematological disorders. Performed at NABH- and JCI-accredited hospitals across India and DHA/JCI-accredited facilities in the UAE, the procedure follows stringent WHO and AABB blood safety protocols, with transfusion-transmitted infection rates below 0.001% per unit at leading centers. GAF Healthcare connects international patients with high-volume transfusion medicine specialists and hematology units where component therapy, leukoreduction, irradiation, and pathogen-reduction technologies ensure the highest standards of blood product safety available globally.

Hospital Stay

1–3 days

Success Rate

99%

Available in

India & UAE

Blood Transfusion in India

Get Blood Transfusion at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.

Blood Transfusion in UAE

Blood Transfusion at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.

Overview

Hospital Stay: 1–5 days (varies by underlying diagnosis and number of transfusion sessions required) • Total Stay in Country (Fit-to-Fly): 1–2 weeks (patients with stable hemoglobin ≥8 g/dL, no active bleeding, and resolved transfusion reactions are typically cleared for long-haul flight within 7–14 days) • Success Rate: 97–99% (defined as achievement of target hemoglobin increment or correction of coagulopathy without serious transfusion-related adverse events)

What Is It?

Blood transfusion is a life-sustaining therapeutic intervention that replaces deficient or dysfunctional blood components. Clinically, it is indicated when the body's oxygen delivery is compromised — most commonly when hemoglobin falls below 7 g/dL in symptomatic patients, or below 8 g/dL in those with cardiovascular disease — or when coagulation factors are depleted due to massive hemorrhage, disseminated intravascular coagulation (DIC), or hepatic failure. Modern transfusion medicine has moved decisively away from whole-blood transfusion toward component therapy, where each fraction (red cells, platelets, plasma, or clotting factor concentrates) is prescribed precisely to address the patient's specific deficit, minimizing volume overload and immunological exposure.

The physiological impact of anemia extends well beyond fatigue: tissue hypoxia accelerates cardiac remodeling, impairs wound healing, reduces chemotherapy tolerance, and independently predicts surgical mortality. Similarly, uncorrected thrombocytopenia (platelets <10,000/µL) or coagulopathy (INR >1.5) in a peri-procedural setting carries substantial hemorrhagic risk. Transfusion medicine specialists use validated scoring systems — including the Patient Blood Management (PBM) algorithm, the ROTEM/TEG (thromboelastography) viscoelastic assay, and the Trauma-Associated Severe Hemorrhage (TASH) score — to determine the precise component, dose, and rate of transfusion required, moving beyond empirical prescribing to individualized, evidence-based therapy.

At NABH- and JCI-accredited hospitals in India, and DHA/JCI-accredited hospitals in the UAE, transfusion services operate under a closed-loop electronic blood bank management system. Every unit of blood is subjected to mandatory nucleic acid testing (NAT) for HIV, HBV, HCV, and malaria; leukoreduction via bedside or pre-storage filtration; and, where clinically indicated, gamma irradiation (25–50 Gy) to prevent transfusion-associated graft-versus-host disease (TA-GvHD) in immunocompromised recipients. Pathogen-reduction technologies (e.g., Intercept Blood System for platelets and plasma) are available at select tertiary centers, further reducing residual infectious risk. This infrastructure positions both India and the UAE as reliable, high-safety destinations for patients requiring elective or urgent transfusion support.

Candidates

ELIGIBLE PATIENTS (Indications for Transfusion):

• Symptomatic anemia with hemoglobin <7 g/dL (or <8 g/dL in patients with ischemic heart disease, COPD, or recent major surgery)

• Acute hemorrhage with estimated blood loss >30% circulating volume (Class III–IV hemorrhagic shock)

• Hemolytic anemia refractory to medical management: autoimmune hemolytic anemia (AIHA), sickle cell disease (exchange transfusion protocol), thalassemia major (chronic transfusion program, target Hb 9–10 g/dL pre-transfusion)

• Thrombocytopenia with platelets <10,000/µL (prophylactic) or <50,000/µL in the peri-procedural/active bleeding setting

• Coagulopathy: FFP indicated for INR >1.5 with active bleeding or planned invasive procedure; cryoprecipitate for fibrinogen <1.5 g/L or factor VIII/XIII deficiency

• Patients undergoing high-blood-loss oncology surgery (hepatectomy, Whipple procedure, cytoreductive surgery with HIPEC)

• Bone marrow failure syndromes: aplastic anemia, myelodysplastic syndrome (MDS), post-chemotherapy/bone marrow transplant cytopenias

• Neonatal hyperbilirubinemia requiring exchange transfusion

• Pre-operative autologous blood donation (PAD) program candidates (elective orthopedic or cardiac surgery)

REQUIRED PRE-TRANSFUSION DIAGNOSTICS:

• Complete blood count (CBC) with reticulocyte count and peripheral blood smear

• ABO and Rh(D) blood grouping and antibody screen (type and screen); crossmatch (type and crossmatch) for pRBC transfusion

• Direct Antiglobulin Test (DAT/Coombs) if hemolytic anemia suspected

• Coagulation profile: PT/INR, aPTT, fibrinogen, thromboelastography (ROTEM/TEG) for complex coagulopathy

• Renal and liver function tests (impacts transfusion rate tolerance)

• Serum ferritin, iron studies, B12, folate (to identify and correct reversible causes before transfusion)

• Infectious disease screening: HIV, HBsAg, HCV Ab, malaria antigen/PCR (especially for patients from endemic regions)

• Echocardiography (ECHO) for patients with cardiac dysfunction to assess TACO (Transfusion-Associated Circulatory Overload) risk

• Hemoglobin electrophoresis / HPLC for suspected hemoglobinopathy

CONTRAINDICATIONS / SITUATIONS REQUIRING ALTERNATIVE STRATEGIES:

• Patients refusing blood products on religious or personal grounds (Jehovah's Witness patients): GAF Healthcare centers offer bloodless medicine programs using erythropoiesis-stimulating agents (ESAs), IV iron sucrose, tranexamic acid, intraoperative cell salvage, and acute normovolemic hemodilution (ANH)

• Iron-deficiency anemia correctable with IV iron therapy alone (avoid unnecessary transfusion)

• Congestive heart failure with volume overload (transfusion requires diuretic cover and slower rate; relative contraindication)

• Active hemolytic transfusion reaction or anaphylaxis to prior blood products (requires antigen-negative or washed red cell units)

• IgA deficiency with anti-IgA antibodies (requires IgA-deficient donor blood or washed red cells)

Procedure

COMPONENT THERAPY APPROACHES:

1. PACKED RED BLOOD CELLS (pRBCs) — Standard Approach: Leukoreduced pRBCs (storage up to 42 days in SAGM additive solution) are the first-line treatment for symptomatic anemia and hemorrhage. One unit raises hemoglobin by approximately 1 g/dL in a 70 kg adult. Bedside leukocyte filtration reduces febrile non-hemolytic transfusion reactions (FNHTRs) by >85%. Pre-storage leukoreduction (performed in the blood bank before storage) is the gold standard at NABH/JCI-accredited hospitals and virtually eliminates CMV transmission risk. For chronically transfused patients (thalassemia, sickle cell disease), extended antigen matching (Rh, Kell, Duffy, Kidd, MNS systems) is performed to prevent alloimmunization.

2. PLATELET TRANSFUSION: Platelets are provided as either pooled random-donor platelets (4–6 units) or single-donor apheresis platelets (preferred, as they reduce donor exposure and alloimmunization risk). Apheresis platelets are collected using automated cell separator machines (Haemonetics MCS+, Trima Accel, Spectra Optia) at accredited blood centers. ABO-compatible and HLA-matched platelets are used for refractory thrombocytopenia due to HLA alloimmunization. Pathogen-reduced platelets (Intercept/Mirasol systems) are available at select UAE and Indian tertiary centers.

3. FRESH FROZEN PLASMA (FFP) & VARIANTS: FFP contains all coagulation factors and is indicated for multiple factor deficiencies. Solvent/detergent-treated pooled plasma (Octaplas) — available at major centers in India and the UAE — offers superior viral safety and standardized factor levels. Methylene blue-treated plasma is used in some UAE facilities for single-unit viral inactivation.

4. CRYOPRECIPITATE: A cold-precipitated fraction of FFP, rich in fibrinogen (150–250 mg/unit), Factor VIII, vWF, Factor XIII, and fibronectin. Indicated in DIC, afibrinogenemia, and von Willebrand disease type 3 when fibrinogen <1.5 g/L.

5. EXCHANGE TRANSFUSION (Automated Erythrocytapheresis): Used in sickle cell disease (HbSS) to rapidly reduce HbS% to <30% (target in acute chest syndrome, stroke, priapism, or pre-operatively). Performed using apheresis machines (Spectra Optia with continuous-flow technology), replacing the patient's sickle cells with normal donor red cells in a single procedure of 3–4 hours. This advanced approach reduces iron loading compared to simple transfusion.

6. MASSIVE TRANSFUSION PROTOCOL (MTP): Activated for hemorrhagic shock requiring >10 units pRBC in 24 hours. Modern MTPs use a balanced ratio of pRBC:FFP:Platelets of 1:1:1 (damage control resuscitation), guided by point-of-care ROTEM/TEG viscoelastic testing to individualize component ratios. Tranexamic acid (1g IV within 3 hours of injury onset, per CRASH-2 protocol) is administered concurrently to inhibit fibrinolysis.

7. PATIENT BLOOD MANAGEMENT (PBM) — Advanced/Integrated Approach: PBM is a multidisciplinary, evidence-based strategy to minimize allogeneic blood use. Pillars include: (a) pre-operative optimization of hemoglobin with IV iron ± ESAs (epoetin alfa/darbepoetin); (b) intraoperative cell salvage (autotransfusion) using devices like the Cell Saver Elite; (c) acute normovolemic hemodilution (ANH); (d) surgical hemostasis techniques and topical hemostatic agents (fibrin sealants, TachoSil). PBM programs at NABH/JCI hospitals in India have demonstrated 30–50% reduction in allogeneic transfusion rates in elective cardiac and orthopedic surgery.

8. IRRADIATED & CMV-NEGATIVE BLOOD PRODUCTS: Mandatory for immunocompromised recipients (post-HSCT patients, congenital immunodeficiency, neonates, patients on purine analogue chemotherapy) to prevent TA-GvHD (gamma irradiation at 25 Gy) and CMV transmission (CMV-seronegative or leukoreduced units).

Cost of Blood Transfusion: India vs. UAE

The cost of blood transfusion therapy varies considerably depending on the number of blood product units required, complexity of component processing (irradiation, pathogen reduction, apheresis platelets), duration of hospitalization, and whether ancillary procedures such as exchange transfusion or cell salvage are involved. India offers substantially lower costs — typically 50–65% less than the UAE — while maintaining equivalent safety standards at NABH/JCI-accredited hospitals. The UAE, particularly Dubai (DHA-regulated) and Abu Dhabi (DOH-regulated, HAAD), offers premium private hospital environments with luxury amenities and minimal travel-distance advantage for patients from Europe, the Gulf region, and East Africa. Both destinations are accessible through GAF Healthcare's end-to-end coordination, with transparent, package-based pricing that eliminates hidden billing.

Destination	Estimated Cost (USD)	Key Advantage
India	$400 – $3,500	~56% less than the UAE
UAE (Dubai/Abu Dhabi)	$900 – $8,000	Premium care, JCI/DHA accredited

Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.

Recovery & Aftercare

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 weeks before travel):

• GAF Healthcare coordinator reviews patient's medical records, recent CBC, coagulation profile, and diagnosis remotely.

• Assigned hematologist/transfusion medicine specialist conducts a telemedicine consultation to confirm transfusion indication, estimate number of sessions, and plan component type.

• Blood group and antibody screen results from the patient's home country are reviewed; where unusual alloantibodies are identified, the receiving blood bank is alerted to source antigen-negative units in advance.

• e-Medical Visa application initiated for India; entry/visa-on-arrival arranged for UAE.

• Pre-admission checklist issued: required documents, dietary guidance, medication reconciliation (hold anticoagulants if procedural transfusion support planned).

PHASE 2 — ARRIVAL & ADMISSION (Day 1):

• Airport transfer by GAF Healthcare ground team; dedicated medical coordinator assigned.

• In-hospital type and crossmatch (ABO/Rh confirmation and antibody screen) performed on fresh sample — mandatory even if prior results are available, per AABB standards.

• Baseline vitals, weight, ECHO (if TACO risk), and IV access (minimum 18G peripheral cannula or PICC line for multi-session patients) established.

• Informed consent process completed by transfusion medicine physician; patient educated on signs of acute transfusion reactions (fever, chills, urticaria, dyspnea, back pain).

PHASE 3 — TRANSFUSION PROCEDURE (Day 1–3, per protocol):

• Blood product issued from blood bank after final electronic verification (two-nurse bedside identification check using barcode/RFID scanning — standard at NABH/JCI facilities).

• Pre-medication (antihistamine ± acetaminophen) administered if patient has prior FNHTR history.

• pRBC transfused over 2–4 hours per unit (slower, 4–6 hours, if cardiac compromise); vital signs monitored at 0, 15, 30 minutes and every hour.

• Platelet transfusion over 20–30 minutes with 1-hour post-transfusion platelet increment (PPI) check to confirm response.

• FFP/cryoprecipitate transfused over 30–60 minutes with repeat coagulation studies 1 hour post-infusion.

• For exchange transfusion (apheresis): 3–4 hour session in the apheresis unit; continuous hemodynamic monitoring; post-procedure HbS% quantified by HPLC.

• Any transfusion reaction triggers immediate cessation, clinical assessment, blood bank notification, and investigation (repeat crossmatch, DAT, plasma hemoglobin, urinalysis for hemoglobinuria).

PHASE 4 — POST-TRANSFUSION ASSESSMENT (Day 2–5):

• Post-transfusion CBC at 24 hours: target hemoglobin increment of ~1 g/dL per unit pRBC confirmed.

• Coagulation re-check after FFP/cryoprecipitate to confirm factor correction.

• Ferritin and iron studies reviewed; IV iron therapy initiated if iron-deficiency coexists.

• Patients on chronic transfusion programs (thalassemia, MDS): chelation therapy assessment (serum ferritin, liver iron concentration by MRI T2*); deferasirox or deferoxamine prescribed as indicated.

• ECHO repeated if TACO was suspected.

• Transfusion reaction workup finalized and documented.

PHASE 5 — DISCHARGE & FIT-TO-FLY ASSESSMENT (Day 5–14):

• Discharge criteria: hemoglobin ≥8 g/dL (or target-specific), no active bleeding, stable vitals, no ongoing transfusion reaction.

• Fit-to-fly assessment by treating physician: patients with hemoglobin ≥8 g/dL and resolved symptoms are cleared for commercial flight (cabin PO2 equivalent to altitude 6,000–8,000 ft); patients with hemoglobin <8 g/dL or significant cardiopulmonary comorbidity may require oxygen supplementation during flight or extended stay.

• Discharge summary, transfusion records, blood bank reports, and follow-up plan provided in English + patient's home language by GAF coordinator.

• Follow-up telemedicine appointment scheduled at 2 and 6 weeks post-discharge.

Risks & Considerations

Blood transfusion is among the safest medical procedures when performed under rigorous protocols, but patients and clinicians must remain vigilant about a defined spectrum of adverse events. Acute hemolytic transfusion reaction (AHTR) — caused by ABO-incompatible transfusion — is rare (1 in 250,000–1,000,000 units) but potentially fatal, manifesting as fever, rigors, back pain, hemoglobinuria, and DIC; it is almost entirely preventable through strict bedside patient identification protocols and electronic verification systems used at NABH/JCI hospitals. Febrile non-hemolytic transfusion reactions (FNHTRs) occur in 0.1–1% of red cell transfusions and are substantially reduced by pre-storage leukoreduction. Transfusion-related acute lung injury (TRALI), characterized by non-cardiogenic pulmonary edema within 6 hours of transfusion, is the leading cause of transfusion-related mortality globally; mitigation strategies include preferential use of male-donor or pathogen-reduced plasma and platelets at accredited centers. Transfusion-associated circulatory overload (TACO) — pulmonary edema from volume excess — is increasingly recognized, particularly in elderly patients and those with cardiac dysfunction; it is managed by slowing transfusion rate, diuretic co-administration, and ECHO-guided volume assessment. Allergic reactions, ranging from urticaria (1–3%) to anaphylaxis (<1 in 20,000), are managed with antihistamines and, in severe cases, epinephrine. Bacterial contamination risk is highest for platelets stored at room temperature (22°C for up to 5–7 days); pathogen-reduction technologies and bacterial detection systems (BacT/ALERT) are employed at leading centers to mitigate this. Transfusion-transmitted infections (TTIs — HIV, HBV, HCV) are now exceptionally rare in accredited blood banking systems using NAT screening, with residual risk below 1 in 1,000,000 units for HIV. Chronic transfusion-related iron overload (hemosiderosis) is a significant long-term complication in patients receiving repeated transfusions (e.g., thalassemia, MDS), requiring regular ferritin monitoring and iron chelation therapy. Alloimmunization — development of red cell alloantibodies against minor blood group antigens — occurs in 1–3% of transfused patients per episode and can complicate future crossmatching and increase hemolytic risk; extended antigen matching minimizes this in chronically transfused patients. Patients should disclose all prior transfusion history, known alloantibodies, and adverse reactions to the GAF Healthcare team before travel to ensure optimal donor unit selection.

Top Hospitals for Blood Transfusion

The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.

🇮🇳

Apollo Hospitals

New Delhi, India

JCI NABH

🇮🇳

Tata Memorial Hospital

Mumbai, India

NABH

🇮🇳

Manipal Hospitals Dwarka

New Delhi, India

NABH NABL

🇦🇪

Burjeel Hospital for Advanced Surgery Dubai

Dubai, UAE

Hospital Certificates of Services

Top Doctors for Blood Transfusion

Internationally trained specialists in Hematology. Review their profiles, compare experience, and connect directly through GAF Healthcare.

Dr. Rahul Bhargava

MBBS, MD (General Medicine), DM (Clinical Hematology), Advanced Fellowship in Unrelated and Haploidentical Transplant

Hematologist & BMT Specialist

Fortis Memorial Research Institute, Gurgaon, India

20+ Yearsof experience

Dr. Rahul Bhargava is a leading Hematologist and BMT specialist currently working at Fortis Memorial Research Institute, Gurugram. With an experience of more than 20 years in Hematology, Pediatric Hemato-Oncology, and Bone Marrow Transplantation, he has performed numerous BMTs with consistently successful outcomes and is widely regarded as one of the most trusted names in this highly specialised field in India. He primarily specialises in haploidentical… Read more

Dr. Vikas Dua

MBBS, MD (Paediatrics), FNB (Paediatric Hematology Oncology), Fellowship in Paediatric Bone Marrow Transplant, Outreach Programme in Paediatric BMT

Pediatric Hematologist & BMT Specialist

Fortis Memorial Research Institute, Gurgaon, India

20+ Yearsof experience

Dr. Vikas Dua is one of the leading paediatric hemato-oncologists and bone marrow transplant specialists of his generation. He currently serves as Principal Director & Head — Paediatric Haematology, Haemato-Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurgaon. Dr. Dua and his team have performed more than 1,200 transplants, with outcomes among the best in the field of paediatric haematology, oncology and BMT. He is… Read more

Dr. Amita Mahajan

MBBS, MD (Pediatrics), MRCPCH, CCST (Advanced Training in Pediatric Oncology)

Pediatric Hematologist and Oncologist

Indraprastha Apollo Hospital, New Delhi, India

32+ Yearsof experience

Dr. Amita Mahajan is a Senior Consultant in Pediatric Hematology and Oncology at Indraprastha Apollo Hospital, New Delhi, with over 32 years of dedicated clinical experience in childhood blood disorders and cancers. She completed her MBBS and MD in Pediatrics from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by advanced international training: the MRCPCH from the Royal College of Paediatrics and Child Health, London, and… Read more

Dr. Govind Eriat

MBBS, DNB, FRCP, Fellowship in Leukemia/BMT

Hematologist & Hemato-Oncologist

Gleneagles Hospitals, Bengaluru, India

14+ Yearsof experience

Dr. Govind Eriat is a Visiting Consultant in Hematology and Hemato-Oncology at Gleneagles Hospitals, Bengaluru, bringing over 14 years of specialized clinical experience in blood disorders and cancer care. He holds an MBBS degree and has completed his DNB in Internal Medicine, establishing a strong foundation in comprehensive patient care. His international credentials include Fellowship from the Royal College of Physicians (FRCP), United Kingdom, and a… Read more

Dr. K. Karuna Kumar

MD, DNB Clinical Hematology

Hematologist

Yashoda Hospitals, Secunderabad, Hyderabad, India

18+ Yearsof experience

Dr. K. Karuna Kumar is a Clinical Consultant in Hematology with over 18 years of specialised clinical experience. He holds an MD from Nizam's Institute of Medical Sciences (NIMS), Hyderabad, and a DNB in Clinical Hematology from Narayana Hrudayalaya, Bangalore—two of India's most prestigious medical institutions. His training has equipped him with exceptional expertise in both benign and malignant blood disorders, as well as complex transplant procedures.… Read more

Frequently Asked Questions — Blood Transfusion

The cost of blood transfusion therapy in India at NABH/JCI-accredited hospitals typically ranges from USD 400 to USD 3,500, depending on the number of units transfused, the type of blood components required (e.g., standard leukoreduced packed red blood cells vs. irradiated, pathogen-reduced, or apheresis platelets), the complexity of the protocol (single transfusion episode vs. exchange transfusion via apheresis vs. multi-day Massive Transfusion Protocol support), and the duration of hospitalization. This cost includes blood bank processing fees, bedside nursing monitoring, IV consumables, pre- and post-transfusion laboratory investigations (CBC, crossmatch, coagulation studies), and standard medications. In the UAE (Dubai or Abu Dhabi), the same scope of care at JCI/DHA-accredited private hospitals ranges from USD 900 to USD 8,000 — approximately 50–65% higher than India — reflecting the premium pricing structure of Gulf healthcare, luxury hospital infrastructure, and higher operational costs. For patients requiring chronic transfusion programs (e.g., thalassemia major receiving transfusions every 3–4 weeks, or MDS patients), the annual cost differential between India and the UAE can be substantial, making India an especially compelling destination for long-term treatment planning. GAF Healthcare provides transparent, itemized cost estimates before travel so patients can plan accurately with no hidden charges.

For the majority of patients undergoing a straightforward elective transfusion (1–3 units of packed red blood cells for symptomatic anemia), the total in-country stay required before being cleared for long-haul international flight is typically 5–10 days. The key fit-to-fly criteria assessed by the treating hematologist are: (1) post-transfusion hemoglobin ≥8 g/dL — this threshold is critical because commercial aircraft cabin pressure is equivalent to an altitude of approximately 6,000–8,000 feet, where ambient oxygen partial pressure is reduced, and patients with hemoglobin below this level risk in-flight hypoxemia; (2) absence of active bleeding, hemolytic reaction, or respiratory compromise; (3) stable vital signs for at least 48 hours post-transfusion; and (4) no ongoing requirement for further transfusion sessions. Patients who have undergone automated exchange transfusion for sickle cell disease are typically cleared to fly within 7–10 days once HbS% has been confirmed below 30% by HPLC and clinical stability is established. Patients receiving their first session of a chronic transfusion program (thalassemia, MDS) may be discharged in 3–5 days with a planned return for subsequent sessions. Patients with concurrent conditions such as heart failure, acute chest syndrome, or severe coagulopathy requiring extended management may need a 2–4 week stay. GAF Healthcare's medical team coordinates directly with the treating physician to provide each patient with an individualized fit-to-fly certificate and, where needed, arranges in-flight supplemental oxygen through the airline's medical desk.

At NABH/JCI-accredited hospitals in India and DHA/JCI-accredited hospitals in the UAE, blood transfusion therapy achieves a procedural success rate of 97–99% when success is defined as: (a) achievement of the target hemoglobin increment (approximately 1 g/dL per unit of packed red blood cells in a standard 70 kg adult); (b) correction of the presenting coagulopathy to within safe range (INR <1.5 after FFP, fibrinogen ≥1.5 g/L after cryoprecipitate, platelet count above the therapeutic threshold after platelet transfusion); or (c) resolution of the hemorrhagic or hypoxic clinical emergency without serious transfusion-related adverse events. Serious adverse events — including acute hemolytic transfusion reactions, TRALI, and anaphylaxis — occur in fewer than 0.1–0.5% of transfusion episodes at accredited centers using NAT-screened blood products, pre-storage leukoreduction, and mandatory electronic bedside verification. It is important to understand that transfusion is a therapeutic intervention, not a cure for the underlying cause of anemia or coagulopathy; the success of the overall treatment plan depends on concurrent management of the root cause (e.g., iron supplementation for iron-deficiency anemia, chemotherapy for bone marrow infiltration, surgical hemostasis for traumatic hemorrhage). GAF Healthcare-affiliated hematologists provide a comprehensive treatment plan addressing both the immediate transfusion need and the long-term management strategy, including monitoring for iron overload in patients on chronic transfusion programs and initiation of chelation therapy (deferasirox, deferoxamine) when serum ferritin exceeds 1,000 ng/mL.

Why Plan Your Treatment Through Gaf Healthcare?

GAF Healthcare provides fully integrated non-medical support to ensure that international patients focus exclusively on their recovery.

VISA & ENTRY ASSISTANCE:

• India: GAF Healthcare facilitates the e-Medical Visa application (available to nationals of 150+ countries), a dedicated visa category that permits 3 entries over 60 days specifically for medical treatment. The visa can typically be obtained within 3–5 business days via the Indian government's online portal, and our coordinators assist with preparing the required hospital invitation letter, treatment cost estimate, and supporting documents.

• UAE (Dubai/Abu Dhabi): Citizens of 50+ countries receive a visa-free entry or visa-on-arrival (30 days) for the UAE. For patients from other regions, GAF Healthcare coordinates a medical visit visa through the sponsoring hospital's international patient services desk under DHA or DOH frameworks. Our team ensures all required insurance, accommodation, and hospital booking documents are in order prior to departure.

AIRPORT TRANSFERS & GROUND LOGISTICS:

• Private, medically equipped vehicle transfers from the airport to the hospital on arrival and from the hospital to the airport at discharge — available 24/7.

• For patients arriving in a medically compromised state (severe anemia, post-chemotherapy), arrangements for wheelchair assistance, stretcher transport, or ambulance transfer are coordinated in advance with the hospital's international patient department.

DEDICATED MEDICAL COORDINATORS & INTERPRETERS:

• Each patient is assigned a personal GAF Healthcare medical coordinator who is present throughout the hospital stay, attends consultations with the treating hematologist, and serves as the liaison between the clinical team and the patient's family.

• Professional medical interpreters are available for Arabic, Russian, French, Swahili, Bangla, Amharic, and 12 other languages — not AI translation tools, but trained clinical translators familiar with hematology terminology.

ACCOMMODATION FOR PATIENT ATTENDANTS:

• GAF Healthcare maintains negotiated rates at partner hotels and serviced apartments within 0.5–2 km of all affiliated hospitals in Mumbai, Delhi, Chennai, Hyderabad, Bangalore (India) and Dubai, Abu Dhabi (UAE).

• For in-patient stays of less than 5 days, most hospitals offer in-room attendant cot/fold-out arrangements at no additional charge.

• For multi-week stays (chronic transfusion programs, patients undergoing concurrent oncology treatment), long-stay apartment options are curated by our team with daily meal planning, laundry, and local SIM card provision.

TELEMEDICINE & FOLLOW-UP:

• Post-discharge teleconsultation with the treating specialist is scheduled at 2 weeks and 6 weeks via GAF Healthcare's encrypted video platform, ensuring continuity of care between the treating hospital and the patient's home physician.

Patients Also Explore

Other treatments commonly sought by patients considering Blood Transfusion.

Breast Cancer Treatment

Cancer Care

Lung Cancer Treatment

Cancer Care

Liver Transplant

Transplant

Lung Transplant

Transplant

Bone marrow transplant cost in India by type, condition and city — what's included, what drives the price, and how it compares with the UK and USA. 2026 guide.

Read Guide